Expression and significance of MAGE genes in human lung cancer

Chinese Journal of Lung Cancer

Volumn 16, Issue 6, 2013, Pages 308-313

  Li, Guangxu ^a,b   Song, Pingping ^b   Zhang, Baijiang ^b  

^a UNIVERSITY OF JINAN   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Active immunotherapy; Lung neoplasms; Melanoma associated antigens genes; Micrometastasis

Indexed keywords

MELANOMA ANTIGEN; MELANOMA-SPECIFIC ANTIGENS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

ARTICLE; CANCER GROWTH; GENE EXPRESSION; LUNG CANCER; PROGNOSIS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; PATHOLOGY;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA-SPECIFIC ANTIGENS; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84940325596     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.l009-3419.2013.06.07     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012,62(1): 10-29.
2. Fazi F, Fontemaggi G. MicroRNAs and lymph node metastatic disease in lung cancer. Thorac Surg Clin, 2012, 22(2): 167-175.
3. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol, 2010, 6(5): 717-732.
4. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGEAl, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res, 2006, 4(5): 339-349.
5. Yanagawa N, Tamura G, Oizumi H, etal. MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res, 2011, 3l(l): 171-175.
6. Shin KC, Lee KH, Lee CH, et al. MAGE A1-A6 RT-PCR and MAGE A3 and pl6 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases. Oncol Rep, 2012, 27(4): 911-916.
7. Karimi S, Mohammadi F, Porabdollah M, et al. Characterization of melanoma-associated antigen-a genes family differential expression in non-small-cell lung cancers. Clin Lung Cancer, 2012, 13(3): 214-219.
8. Kim H, Kim SJ, Lee SH, et al. Usefulness of melanoma antigen (MAGE) gene analysis in tissue samples from percutaneous needle aspiration biopsy of suspected lung cancer lesions. Lung Cancer, 2010, 69(3): 284-288.
9. Han XJ, Lin YE, Xiang B, et al. Clinical significance of MAGE-A3 and AKAP-4 in non-small cell lung carcinoma. Re Dai Yi Xue Za Zhi, 2012, 12(9): 1068-1070.
10. Shin KC, Choi EY, Chung JH, et al. Clinical application of MAGE Al-6 RT-nested PCR for diagnosis of lung cancer invisible by bronchoscopy Anticancer Res, 2012, 32(1): 163-167.
11. Liu T, Guo JJ. MRNA expression of MAGE-1 gene in peripheral blood of non-small cell lung cancer. Lin Chuang Fei Ke Za Zhi, 2012, 17(6): 1141-1142.
12. Song JQ Li H, Wang QH, et al. Study on demethylation status of MAGE genes promoter in peripheral blood of patients with non-small cell lung cancer. Zhonghua Lin Chuang Yi Shi Za Zhi (Electronic Edition), 2012, 6(18): 5475-5478.
13. Dango S, Wang XT, Gold M, et al. Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer. Lung Cancer, 2010, 67(3): 290-295.
14. Cucuruz B, Dango S, Jurinovic V, etal. MAGE qPCR improves the sensitivity and accuracy of EBUS-TBNA for the detection of lymphatic cancer spread. J Thorac Oncol, 2012, 7(4): 690-697.
15. Xian L, Wang J, Jiang GC, et al. Detection of occult micrometastasis using MAGE genes in lymph nodes of patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 2005, 8(3): 219-222.
16. Curioni-Fontecedro A, Nuber N, Mihic-Probst D, et al. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One, 2011, 6(6): e21418.
17. Badovinac Crnjevic T, Spagnoli G, Juretic A, et al. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med Oncol, 2012, 29(3): 1586-1591.
18. Zhang Y, Li Q, Liu N, etal. Detection of MAGE-1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous icrometastasis of hepatocellular carcinoma. Hepatogastroen-terology, 2008, 55(88): 2200-2206.
19. Dyrskjot L, Zieger K, Kissow Lildal T, et al. Expression of MAGE-A3, NY ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer, 2012, 107(1): 116-122.
20. Yang B, O'Herrin SM, Wu J, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res, 2007, 67(20): 9954-9962.
21. Marcar L, Maclaine NJ, Hupp TR, et al. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res, 2010,70(24): 10362-10370.
22. Sang MX, Shan BE, Geng CZ, et al. Effect of melanoma antigen MAGE-A4 on the transcriptional activity of p53. Zhong Liu, 2009, 29(5): 428-432.
23. Liu W, Cheng S, Asa SL, et al. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res, 2008, 68(19): 8104-8112.
24. Hamai A, Pignon P, Raimbaud I, et al. Human T(H) 17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-y-secreting cells as they differentiate into effector T cells in vivo. Cancer Res, 2012, 72(5): 1059-1063.
25. Baba T, Shiota H, Kuroda K, et al. Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients. Int J Clin Oncol, 2012 Nov 3. [Epub ahead of print].
26. Peikert T, Specks U, Farver C, et al. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res, 2006, 66(9): 4693-4700.
27. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-A3 and presented by HLA-A1. Int J Cancer, 1999, 80(2): 219-230.
28. Glynn SA, Gammell P, Heenan M, et al. A new superinvasive in vitro phe-notype induced by selection of human breast carcinoma cells with the che-motherapeutic drugs paclitaxel and doxorubicin. Br J Cancer, 2004, 9l(l0): 1800-1807.
29. Ueda Y, Shimizu K, Itoh T, et al. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol, 2007, 37(2): 140-145.
30. Wojas-Krawczyk K, Krawczyk P, Buczkowski J, et al. Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report. Arch Immunol TherExp (Warsz), 2012, 60(l): 69-77.
31. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clinl Oncol, 2007, 28(l8S): abstr 7554.
32. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy Clin Lung Cancer, 2009, 10(5): 371-374.